Revolutionizing the Future of Dermatology
Skinopathy was founded in the Summer of 2020 with one simple objective:
Create artificial intelligence that can be used by physicians, nurses, and patients to pre-screen for skin cancers.
Since then, the medical community, private sector, and government agencies from all corners of the World have rallied behind Skinopathy and asked us to expand our offerings because of our abilities.
In fact, our approach to medtech has consistently led our peers to label Skinopathy as a “One-of-One” since it finally brings together:
Skinopathy has been so incredibly successful because of our team. And because of our people we have adopted an approach that makes us unique in the industry.
Healthcare Practitioners ensure our technology is effective, relevant, and always focused on the patient.
Our Engineers ensure our technology is agile, modular, and always secure.
Our Researchers ensure our technology is proven, trustworhty, and always backed by research.
Please click on the link below for any press and investment inquiries.